Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic Cardiomyopathy

NCT01556568 is registered in ClinicalTrials.gov with Array Biopharma, now a wholly owned subsidiary of Pfizer as lead sponsor.

NCT NCT01556568
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01556568 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic Cardiomyopathy
Lead sponsor
Array Biopharma, now a wholly owned subsidiary of Pfizer
Phase
Phase 2
Overall status
Withdrawn
Start date
February 29, 2012
Completion date
Not reported
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cardiomegaly